

# Community Guidelines

Welcome to Amarin’s social media channels, where you will find our latest company news, data releases and employee activities. Our social media presence is an important way for us to interact and communicate transparently with stakeholders who seek to find out more about us, including patients, caregivers, healthcare providers, investors and others.

As a pharmaceutical company, we are mindful of the regulations that govern our industry and all comments submitted to our social media platforms are monitored for appropriateness. We encourage you to join the conversation, but please know that when you engage, you are agreeing to our Community Guidelines, as outlined below. These guidelines apply to all social media platforms, including but not limited to Twitter, Facebook and LinkedIn. Please read through these guidelines and check back from time to time as they may change.

1. Due to the regulatory environment in which we operate, we cannot offer medical advice or otherwise engage in a promotion or discussion about products or treatment options – ours or other companies’ – on our social media platforms. Any information presented on our social media platforms should not serve as a substitute for discussions with your doctor. If you have questions about a medical condition please speak to a qualified healthcare professional.
2. We consider **the following content (below) unacceptable** and reserve the right to delete content or block users who violate these terms:
  - Content that is misleading, fraudulent or deceptive
  - Content that contains language that is obscene, offensive, defamatory, libelous, abusive, discriminatory, disparaging, threatening or disruptive to the community and/or Amarin Corporation (including images, videos and links)
  - Promotional content concerning products or services
  - Content that names or references any medications, treatments or medical devices, including those in development or that have been developed or marketed by Amarin
  - Content that contains medical advice
  - Posts that are excessively repetitive, irrelevant, politically driven, unrelated to content on the page, disruptive to the community and/or are spam-like in nature
  - Posts that contain links, including those to videos, not owned by Amarin
  - Posts that include messages that contain any personal, proprietary or sensitive information about or related to Amarin, its affiliates or any other person or company
  - Posts that are related to current or future litigation in which Amarin or its affiliates are involved
  - Posts that violate [LinkedIn’s User Agreement](#), [Facebook’s Terms of Service](#), and [Twitter’s Terms of Service](#)

Please note that if you experience a possible side effect from VASCEPA® (icosapent ethyl), you should report this information by calling 1-855-VASCEPA (1-855-827-2372), email [Amarinconnect@amarincorp.com](mailto:Amarinconnect@amarincorp.com), or calling the FDA at 1-800-FDA-1088.

We thank you for taking time to read through our Community Guidelines.